{"protocolSection":{"identificationModule":{"nctId":"NCT06471543","orgStudyIdInfo":{"id":"RN0361-101"},"organization":{"fullName":"Ikaria Bioscience Pty Ltd","class":"INDUSTRY"},"briefTitle":"Study of RN0361 in Adult Subjects","officialTitle":"A Phase 1, Randomized, Single-blinded, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic Effects and Immunogenicity of RN0361 in Adult Subjects With Elevated Triglycerides"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-09-30","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-09-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-06-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-06","studyFirstSubmitQcDate":"2024-06-18","studyFirstPostDateStruct":{"date":"2024-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-18","lastUpdatePostDateStruct":{"date":"2024-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Ikaria Bioscience Pty Ltd","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics， pharmacodynamics and immunogenicity of single and multiple doses of RN0361 in Adult subjects."},"conditionsModule":{"conditions":["Hypertriglyceridemia","Familial Chylomicronemia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":60,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"RN0361","type":"EXPERIMENTAL","description":"subcutaneous injections","interventionNames":["Drug: RN0361"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"calculated volume to match active treatment","interventionNames":["Drug: RN0361"]}],"interventions":[{"type":"DRUG","name":"RN0361","description":"solution","armGroupLabels":["Placebo","RN0361"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Safety and tolerability of RN0361 as evaluated when administered as single and multiple ascending SC doses in healthy adult subjects with elevated triglycerides","description":"Incidence and frequency of adverse events (AEs)/serious adverse events (SAEs) possibly or probably related to treatment of RN0361","timeFrame":"Up to Day85 in Single Ascending-Dose (SAD) and Day113 in the Multiple Ascending Dose (MAD) part. Additionally, there may be an extra follow-up period."},{"measure":"Safety and tolerability of RN0361 as evaluated when administered as single and multiple ascending SC doses in healthy adult subjects with elevated triglycerides","description":"Number of Participants with clinically significant changes in clinical laboratory safety tests (hematology, biochemistry, coagulation, and urinalysis) related to treatment of RN0361","timeFrame":"Up to Day85 in Single Ascending-Dose (SAD) and Day113 in the Multiple Ascending Dose (MAD) part. Additionally, there may be an extra follow-up period."},{"measure":"Safety and tolerability of RN0361 as evaluated when administered as single and multiple ascending SC doses in healthy adult subjects with elevated triglycerides","description":"Number of Participants with clinically significant changes in vital signs (oral body temperature, blood pressure, heart rate, and respiration rate)","timeFrame":"Up to Day85 in Single Ascending-Dose (SAD) and Day113 in the Multiple Ascending Dose (MAD) part. Additionally, there may be an extra follow-up period."},{"measure":"Safety and tolerability of RN0361 as evaluated when administered as single and multiple ascending SC doses in healthy adult subjects with elevated triglycerides","description":"Number of Participants with clinically significant changes in 12-lead electrocardiograms (ECGs)","timeFrame":"Up to Day85 in Single Ascending-Dose (SAD) and Day113 in the Multiple Ascending Dose (MAD) part. Additionally, there may be an extra follow-up period."},{"measure":"Safety and tolerability of RN0361 as evaluated when administered as single and multiple ascending SC doses in healthy adult subjects with elevated triglycerides","description":"Number of Participants with clinically significant changes in physical examinations","timeFrame":"Up to Day85 in Single Ascending-Dose (SAD) and Day113 in the Multiple Ascending Dose (MAD) part. Additionally, there may be an extra follow-up period."},{"measure":"Safety and tolerability of RN0361 as evaluated when administered as single and multiple ascending SC doses in healthy adult subjects with elevated triglycerides","description":"Incidence and frequency of injection site reactions (ISRs)","timeFrame":"Up to Day85 in Single Ascending-Dose (SAD) and Day113 in the Multiple Ascending Dose (MAD) part. Additionally, there may be an extra follow-up period."}],"secondaryOutcomes":[{"measure":"Maximum plasma concentration (Cmax) of single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","description":"Single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","timeFrame":"Up to Day 85 in Part 1 [SAD] and Day 113 in Part 2 [MAD]. Additionally, there may be an extra follow-up period."},{"measure":"Time to reach maximum plasma concentration (tmax) of single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","description":"Single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","timeFrame":"Up to Day 85 in Part 1 [SAD] and Day 113 in Part 2 [MAD]. Additionally, there may be an extra follow-up period."},{"measure":"Area under the plasma concentration-time curve from time zero to 24h post-dose (AUC0-24) of single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","description":"Single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","timeFrame":"Up to Day 85 in Part 1 [SAD] and Day 113 in Part 2 [MAD]. Additionally, there may be an extra follow-up period."},{"measure":"Area under the plasma concentration versus time curve from time zero extrapolated to infinity (AUC0-inf) of single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","description":"Single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","timeFrame":"Up to Day 85 in Part 1 [SAD] and Day 113 in Part 2 [MAD]. Additionally, there may be an extra follow-up period."},{"measure":"Terminal elimination half-life (t1/2) of single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","description":"Single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","timeFrame":"Up to Day 85 in Part 1 [SAD] and Day 113 in Part 2 [MAD]. Additionally, there may be an extra follow-up period."},{"measure":"Elimination rate constant (λz) of single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","description":"Single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","timeFrame":"Up to Day 85 in Part 1 [SAD] and Day 113 in Part 2 [MAD]. Additionally, there may be an extra follow-up period."},{"measure":"Apparent volume of distribution (Vz/F) of single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","description":"Single-dose and multiple-dose plasma PK parameters for RN0361 and its metabolite","timeFrame":"Up to Day 85 in Part 1 [SAD] and Day 113 in Part 2 [MAD]. Additionally, there may be an extra follow-up period."},{"measure":"Renal clearance (CLR) of single-dose and multiple-dose urine PK parameters for RN0361 and its metabolite AS3'N-1","description":"Single-dose and multiple-dose urine PK parameters for RN0361 and its metabolite","timeFrame":"Up to Day 85 in Part 1 [SAD] and Day 113 in Part 2 [MAD]. Additionally, there may be an extra follow-up period."},{"measure":"Amount of drug excreted in the urine over the collection interval t (Aet) of single-dose and multiple-dose urine PK parameters for RN0361 and its metabolite AS3'N-1","description":"Single-dose and multiple-dose urine PK parameters for RN0361 and its metabolite","timeFrame":"Up to Day 85 in Part 1 [SAD] and Day 113 in Part 2 [MAD]. Additionally, there may be an extra follow-up period."},{"measure":"Cumulative amount of drug excreted in urine at the end of each interval (Aeu) of single-dose and multiple-dose urine PK parameters for RN0361 and its metabolite AS3'N-1","description":"Single-dose and multiple-dose urine PK parameters for RN0361 and its metabolite","timeFrame":"Up to Day 85 in Part 1 [SAD] and Day 113 in Part 2 [MAD]. Additionally, there may be an extra follow-up period."},{"measure":"Fraction of dose excreted in the urine over the collection interval (FE) of single-dose and multiple-dose urine PK parameters for RN0361 and its metabolite AS3'N-1","description":"Single-dose and multiple-dose urine PK parameters for RN0361 and its metabolite","timeFrame":"Up to Day 85 in Part 1 [SAD] and Day 113 in Part 2 [MAD]. Additionally, there may be an extra follow-up period."},{"measure":"Cumulative fraction of dose excreted in the urine over collection intervals (FEu) of single-dose and multiple-dose urine PK parameters for RN0361 and its metabolite AS3'N-1","description":"Single-dose and multiple-dose urine PK parameters for RN0361 and its metabolite","timeFrame":"Up to Day 85 in Part 1 [SAD] and Day 113 in Part 2 [MAD]. Additionally, there may be an extra follow-up period."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Willing to provide written informed consent before any study-specific procedures.\n* Comply with the study requirements and restrictions as listed in the Informed Consent Form and the protocol.\n* Fasting serum triglyceride levels \\> 80 mg/dL and fasting LDL-C ≥70 mg/dL at screening\n* Female participants must either be nonchildbearing or, if of childbearing potential, not pregnant, not breastfeeding, and using effective contraception. Male participants must use condoms and ensure their partners use contraception if they are of childbearing potential.\n* Participants must avoid sperm or egg donation during the study\n\nExclusion Criteria:\n\n* History or presence of any serious or uncontrolled disease\n* clinically significant health concerns\n* Recent vaccination with live vaccines, except for influenza, or plans to receive such during the study.\n* Positive tests for alcohol or drugs of abuse at screening.\n* History of multiple drug allergies or allergic reactions to specific components used in the study.\n\nNote: Additional inclusion/exclusion ceiteria may apply, per protocol.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Esther J JIANG","role":"CONTACT","phone":"13916015172","email":"esther.jiang@ronatherapeutics.com"}],"locations":[{"facility":"Nucleus Network Melbourne","city":"Melbourne","state":"Victoria","zip":"3004","country":"Australia","contacts":[{"role":"CONTACT","email":"melbourne@nucleusnetwork.com"}],"geoPoint":{"lat":-37.814,"lon":144.96332}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000008072","term":"Hyperlipoproteinemia Type I"},{"id":"D000015228","term":"Hypertriglyceridemia"}],"ancestors":[{"id":"D000006949","term":"Hyperlipidemias"},{"id":"D000050171","term":"Dyslipidemias"},{"id":"D000052439","term":"Lipid Metabolism Disorders"},{"id":"D000008659","term":"Metabolic Diseases"},{"id":"D000008052","term":"Lipid Metabolism, Inborn Errors"},{"id":"D000008661","term":"Metabolism, Inborn Errors"},{"id":"D000030342","term":"Genetic Diseases, Inborn"},{"id":"D000006951","term":"Hyperlipoproteinemias"}],"browseLeaves":[{"id":"M11072","name":"Hyperlipoproteinemia Type I","asFound":"Familial Chylomicronemia","relevance":"HIGH"},{"id":"M17932","name":"Hypertriglyceridemia","asFound":"Hypertriglyceridemia","relevance":"HIGH"},{"id":"M10000","name":"Hyperlipidemias","relevance":"LOW"},{"id":"M10002","name":"Hyperlipoproteinemias","relevance":"LOW"},{"id":"M26181","name":"Dyslipidemias","relevance":"LOW"},{"id":"M11639","name":"Metabolic Diseases","relevance":"LOW"},{"id":"M27029","name":"Lipid Metabolism Disorders","relevance":"LOW"},{"id":"M11641","name":"Metabolism, Inborn Errors","relevance":"LOW"},{"id":"M11054","name":"Lipid Metabolism, Inborn Errors","relevance":"LOW"},{"id":"M23686","name":"Genetic Diseases, Inborn","relevance":"LOW"},{"id":"T2236","name":"Familial Lipoprotein Lipase Deficiency","asFound":"Familial Chylomicronemia","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC16","name":"Diseases and Abnormalities at or Before Birth"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M21860","name":"Pharmaceutical Solutions","relevance":"LOW"}],"browseBranches":[{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}